Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTX 130 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COBALT-LYM
  • Sponsors CRISPR Therapeutics

    • Most Recent Events

    • 08 Aug 2022 According to a CRISPR Therapeutics media release, the company The Company continues to enroll and dose patients in the dose expansion part of the trial.
    • 17 Jun 2022 Results (n=15; As of 6 Dec, 2021) assessing safety and efficacy of CTX130 in with relapsed/refractory T-cell malignancies, presented at the 27th Congress of the European Haematology Association.
    • 11 Jun 2022 According to a CRISPR Therapeutics media release, data were presented at the Annual European Hematology Association (EHA) 2022 Hybrid Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top